NCT03459391View on ClinicalTrials.gov

Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 22, 2017

Primary Completion Date

September 26, 2017

Study Completion Date

September 26, 2017

Conditions
InfluenzaAcute Respiratory Infection
Interventions
DRUG

XC221 60 mg

The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.

DRUG

XC221 200 mg

The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.

DRUG

Placebo

The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.

Trial Locations (1)

119435

SBEI HPE The First Moscow State Medical University n.a. Sechenov of Ministry of Health of Russian Federation, University Hospital #2, Department of Development of New Medicines, Moscow

All Listed Sponsors
lead

PHARMENTERPRISES LLC

INDUSTRY

NCT03459391 - Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers | Biotech Hunter | Biotech Hunter